Buscar
Mostrando ítems 1-10 de 79
Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
(2018)
Background: Tyrosine kinase inhibitors (TKIs) are effective therapies with demonstrated antineoplastic activity. Nilotinib is a second-generation FDA-approved TKI designed to overcome Imatinib resistance and intolerance ...
The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells
(BioMed Central, 2018)
Abstract
Background
New drugs for adrenocortical carcinoma (ACC) are needed because most patients undergo rapid disease progression despite surgery and adjuvant therapy ...
Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia
(FUTURE MEDICINE LTD, 2011)
Aim: A cost effectiveness analysis was performed to assess the potential value of companion diagnostics in supporting treatment decisions for dasatinib and nilotinib in chronic myeloid leukemia. Materials & methods: A ...
Estudo das potenciais interações medicamentosas (PIM) associadas às alterações da concentração plasmática, eficácia e toxicidade, do imatinibe, dasatinibe e nilotinibe.
(Universidade Federal de São Paulo, 2022-02-08)
A Leucemia Mielóide Crônica (LMC) é uma doença mieloproliferativa clonal, estando diretamente associada à presença do cromossomo Filadélfia (Ph), que é detectado em mais de 90% dos pacientes com LMC e que também é caracterizada ...
Repuesta al tratamiento en leucemia mieloide crónica refractaria mediante cuantificación del Gen BCR/ABL1
(Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados, 2018)
Los pacientes con leucemia mieloide crónica reciben tratamiento con terapia dirigida de primera línea que son los inhibidores de tirosina cinasa de primera y segunda generación, pero pueden presentar refractariedad por ...
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
(Amer Soc HematologyWashingtonEUA, 2013)
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
(Amer Soc HematologyWashingtonEUA, 2014)